Loading...
Loading...
VACC| Name | Value |
|---|---|
| Revenues | 0.3M |
| Cost of Revenue | 13.5M |
| Gross Profit | -13.2M |
| Operating Expense | 26.1M |
| Operating I/L | -26.3M |
| Other Income/Expense | 0.3M |
| Interest Income | 0.5M |
| Pretax | -25.0M |
| Income Tax Expense | -1.1M |
| Net Income/Loss | -23.8M |
Vaccitech plc is a clinical-stage biopharmaceutical company specializing in the development of T cell immunotherapeutics and vaccines for infectious diseases and cancers. The company's portfolio includes therapeutic programs such as VTP-300 for chronic hepatitis B, VTP-200 for human papilloma virus, VTP-850 for prostate cancer, and VTP-600 for non-small cell lung cancer. Additionally, its prophylactic programs consist of VTP-400 for herpes zoster, VTP-500 for Middle East respiratory syndrome prevention, and Vaxzevria, a COVID-19 vaccine. Vaccitech plc generates revenue through the development and commercialization of these innovative immunotherapeutics and vaccines.
